about
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cellsHarnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells.Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.Kaposi's sarcoma-associated herpesvirus vFLIP and human T cell lymphotropic virus type 1 Tax oncogenic proteins activate IkappaB kinase subunit gamma by different mechanisms independent of the physiological cytokine-induced pathwaysMODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.Targeting lentiviral vectors for cancer immunotherapy.Lentiviral vectors for cancer immunotherapy and clinical applicationsThe membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability.Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex.Construction of stable packaging cell lines for clinical lentiviral vector production.Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.Nature of the virus associated with endemic Balkan nephropathy.Immunopurification applied to the study of virus protein composition and encapsidation.Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography.Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
P50
Q28242808-3CC40182-DE0B-4349-9072-3D04FC311114Q30431135-D2CF65F4-2617-49CD-9974-178BD5EBCE60Q33877397-89F82A36-B73D-45D3-A87F-726E25033CD2Q34310345-40EC9CBD-5325-4266-9EA1-922BF845B0C0Q34767725-957D5A8C-94FA-4433-B0B5-CC19D93E22A5Q35077741-9475049F-92B5-49DF-9482-C022B4D3E1C7Q38040302-0C447DCD-25EE-4129-B10D-573789B58C3CQ38043924-F927559A-587A-4A91-99E0-7371E5BAAFA7Q38147100-C5BC7374-A72C-46BC-B54C-7A9F4D802523Q39601876-E6A31BED-CBFA-4FC3-8E41-D7DF93C9C693Q39641093-94B2872A-D88A-4860-801F-D1CFDEDE63DAQ40091540-3345FAA2-F21D-4FC9-AACF-2B58AABAF3ACQ41437137-B32AD2FB-B6A3-40BC-9144-D43B78B352C1Q42110927-84B07B9A-985B-4777-9EA5-7DC7F3814220Q42535970-C28399EE-7A46-42EB-841E-A3E2FC125D53Q45636663-7BC30C12-1940-45CC-A3C0-D9679C7BC315Q48233993-6609AFD1-9951-47AE-88A4-63EAF821F860Q91627354-A5D0A9C6-975B-4EC0-95DB-2A4B84742D64
P50
description
Immunologists and researcher
@en
wetenschapper
@nl
name
David Escors
@ast
David Escors
@en
David Escors
@es
David Escors
@nl
David Escors
@sl
type
label
David Escors
@ast
David Escors
@en
David Escors
@es
David Escors
@nl
David Escors
@sl
altLabel
David Escors Murugarren
@en
David Escors
@en
prefLabel
David Escors
@ast
David Escors
@en
David Escors
@es
David Escors
@nl
David Escors
@sl
P214
P244
P106
P21
P214
P244
n2012186302
P31
P496
0000-0003-2828-4458
P735
P7859
lccn-n2012186302